HARP News and Press, Harpoon Therapeutics Inc. From 03/24/21

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is a...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Harpoon Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association ...

Harpoon Therapeutics, Inc. (HARP) Q4 2020 Earnings Conference Call March 10, 2021, 04:30 PM ET Company Participants Gerald McMahon - President and CEO Georgia Erbez - CFO Natalie Sacks - Chief Medical Officer Holger Wesche - Chief Scientific Officer Conference Call Participants Jonathan Chang...

Harpoon Therapeutics (HARP): Q4 GAAP EPS of -$0.45 beats by $0.11.Revenue of $7.5M (+236.3% Y/Y) beats by $2.32M.Press Release For further details see: Harpoon Therapeutics EPS beats by $0.11, beats on revenue

Provided positive update on its four TriTAC ® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer Nominated first ProTriTAC™ candidate, HPN601 and presented promising precl...

SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate i...

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide ...

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate i...

The FDA has granted Orphan Drug Designation to Harpoon Therapeutics' (HARP) HPN217 for the treatment of multiple myeloma.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.HPN217, a tri-specific T cell activating r...